stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Return on equity
Viridian Therapeutics, Inc.'s return on equity over the twelve months to 30 September 2026 was 0.00%, up 63.9 percentage points from fiscal 2025 (−63.9%). Over the past ten years it has ranged from −138.1% (fiscal 2015) to 2,308.2% (fiscal 2021); the current reading is higher than 64% of that period. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −63.9% | 11.30 |
| FY2024 | −75.2% | 22.18 |
| FY2023 | −97.4% | (12.69) |
| FY2022 | −84.7% | (2,392.84) |
| FY2021 | 2,308.2% | 1,816.22 |
| FY2020 | 492.0% | 616.77 |
| FY2019 | −124.8% | (52.02) |
| FY2018 | −72.8% | (299.32) |
| FY2017 | 226.5% | 159.27 |
| FY2016 | 67.3% | 205.40 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| VRDN Viridian Therapeutics, Inc. | 0.00% |
| TLX Telix Pharmaceuticals Limited compare | 0.00% |
| ELVN Enliven Therapeutics, Inc. compare | −15.3% |
| DNLI Denali Therapeutics Inc. compare | −33.9% |
| IDYA IDEAYA Biosciences, Inc. compare | −38.5% |
| DYN Dyne Therapeutics, Inc. compare | −81.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| TARS Tarsus Pharmaceuticals, Inc. compare | −319.8% |
| CELC Celcuity, Inc. compare | −1,433.7% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on VRDN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement